pole and beyond arcades. This is considered an atypical variant of Best vitelliform macular dystrophy (VMD). [1] This photo essay describes the multimodal imaging (MI) characteristic of MBD.
Case
A 14-year-old male presented with gradual loss of vision in both the eyes for 2 years. Best-corrected visual acuity was 6/18, N6 both eyes. Color fundus photograph [ Fig. 1a and b] showed multiple small round yellow subretinal lesions on the posterior pole extending beyond the arcades along with macular thickening. Multicolor image [ Fig. 1c and d] showed greenish hue over the macula and multiple orange spots corresponding to yellow lesions. Blue-light fundus autofluorescence (FAF) [ Fig. 2a and b] showed multiple hyperautofluorescent lesions. Near-infrared reflectance image [ Fig. 3a and b] showed multiple white hyper-reflective spots suggestive of alterations at retinal pigment epithelium (RPE) level, while green [ Fig. 3c and d] and blue [ Fig. 3e and f] reflectance image Fig. 5a and b] showed no leak. Full-field electroretinography and electro-oculography (EOG) were normal.
Discussion
MBD presents with typical features, has association with VMD2 gene mutation, and may have normal EOG. [2, 3] MI is important to differentiate this entity from acute exudative polymorphous vitelliform maculopathy syndrome, pattern dystrophies, drusenoid pigment epithelial detachment, birdshot chorioretinitis, central serous chorioretinopathy, and paraneoplastic syndromes. [4] Multicolor imaging localizes the lesion to RPE as seen in IR image while Blue Reflectance (BR) and Green Reflectance (GR) which highlight the superficial retinal lesions are silent. [5] EDI-OCT shows characteristic vitelliform deposits with normal subfoveal choroidal thickness and vasculature. FFA and indocyanine green show no leak. FAF is striking and highlights the vitelliform deposits due to their rich lipofuscin content. MBD is primarily a benign condition and does not warrant any treatment unless associated with secondary complications such as choroidal neovascular membrane. Genetic testing can add paramount significance to such cases. [6] 
Conclusion
This report highlights the MI of MBD and will help clinicians to differentiate it from similar lesions.
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